Abstract: Provided herein are methods and systems for the analysis of biomarkers, and methods of providing diagnoses and/or prognoses therewith. In particular, methods and systems for performing biomarker ratio imaging microscopy (BRIM) are provided, as well as methods of using BRIM for the analysis of biomarker pairs (e.g., CD44/CD24, N-cadherin/E-cadherin, CD74/CD59, etc.) diagnosis and/or prognosis of cancer (e.g., ductal carcinoma in situ).

Abstract: Provided herein are methods and systems for the analysis of biomarkers, and methods of providing diagnoses and/or prognoses therewith. In particular, methods and systems for performing biomarker ratio imaging microscopy (BRIM) are provided, as well as methods of using BRIM for the analysis of biomarker pairs (e.g., CD44/CD24, N-cadherin/E-cadherin, CD74/CD59, etc.) diagnosis and/or prognosis of cancer (e.g., ductal carcinoma in situ).

Abstract: Nanoparticles comprising a metal oxide and a platinum cluster having a height to base ratio greater than 1 and compositions containing the same are disclosed. Methods of using the nanoparticles in producing hydroxyl radicals and in photodynamic therapy, for example, in the treatment of hyperproliferative disease such cancer, are also disclosed.

Abstract: Nanoparticles comprising a metal oxide and a platinum cluster having a height to base ratio greater than 1 and compositions containing the same are disclosed. Methods of using the nanoparticles in producing hydroxyl radicals and in photodynamic therapy, for example, in the treatment of hyperproliferative disease such cancer, are also disclosed.

Abstract: A method and apparatus for measuring the retinal auto-fluorescence of a subject retina includes an excitation light source for providing an excitation light at a wavelength of at least 450 nm and an image capture device for recording an ocular auto-fluorescence signal generated in response to the excitation light. The image capture device includes a filter for reducing background non-signal wavelengths from the ocular auto-fluorescence signal and an image intensifier for increasing the ocular auto-fluorescence signal strength. The method and apparatus may further include a processor that analyzes the ocular auto-fluorescence signal to determine a contrast change or pattern to thereby detect retinal disease or damage. The processor may compare the images with control images, past images of the same eye or other diagnostic modalities such as fundus photography, angiography, or visual field testing to detect the retinal disease or damage.

Abstract: Disease may be detected, monitored, etc. by detecting metabolic dysfunction in a patient's eyes. In one embodiment of an apparatus, an excitation light is generated by an excitation light source to induce autofluorescence in an ocular tissue (e.g., retinal tissue), wherein the excitation light excites flavoprotein autofluorescence (FA) and minimizes the excitation of non-flavoprotein autofluorescence. At least a single image representing the induced ocular tissue autofluorescence is captured. The at least single image is intensified to increase the signal strength of the ocular tissue autofluorescence. The at least single image is analyzed to generate an indicator of whether a patient has one or more of eye damage, a disease that causes eye damage, or to generate an indicator of the progression of a disease, an indicator of the effectiveness of a treatment, a personalized treatment for a subject, etc.

Abstract: A method and apparatus for measuring the retinal auto-fluorescence of a subject retina includes an excitation light source for providing an excitation light at a wavelength of at least 450 nm and an image capture device for recording an ocular auto-fluorescence signal generated in response to the excitation light. The image capture device includes a filter for reducing background non-signal wavelengths from the ocular auto-fluorescence signal and an image intensifier for increasing the ocular auto-fluorescence signal strength. The method and apparatus may further include a processor that analyzes the ocular auto-fluorescence signal to determine a contrast change or pattern to thereby detect retinal disease or damage. The processor may compare the images with control images, past images of the same eye or other diagnostic modalities such as fundus photography, angiography, or visual field testing to detect the retinal disease or damage.

Abstract: Disease may be detected, monitored, etc. by detecting metabolic dysfunction in a patient's eyes. In one embodiment of an apparatus, an excitation light is generated by an excitation light source to induce autofluorescence in an ocular tissue (e.g., retinal tissue), wherein the excitation light excites flavoprotein autofluorescence (FA) and minimizes the excitation of non-flavoprotein autofluorescence. At least a single image representing the induced ocular tissue autofluorescence is captured. The at least single image is intensified to increase the signal strength of the ocular tissue autofluorescence. The at least single image is analyzed to generate an indicator of whether a patient has one or more of eye damage, a disease that causes eye damage, or to generate an indicator of the progression of a disease, an indicator of the effectiveness of a treatment, a personalized treatment for a subject, etc.

Abstract: A method and apparatus for measuring the retinal auto-fluorescence of a subject retina includes an excitation light source for providing an excitation light at a wavelength of at least 450 nm and an image capture device for recording an ocular auto-fluorescence signal generated in response to the excitation light. The image capture device includes a filter for reducing background non-signal wavelengths from the ocular auto-fluorescence signal and an image intensifier for increasing the ocular auto-fluorescence signal strength. The method and apparatus may further include a processor that analyzes the ocular auto-fluorescence signal to determine a contrast change or pattern to thereby detect retinal disease or damage. The processor may compare the images with control images, past images of the same eye or other diagnostic modalities such as fundus photography, angiography, or visual field testing to detect the retinal disease or damage.

Abstract: The present invention relates, in general, to phagocytosis and phagolysosomal fusion and, in particular, to a tripeptide of Fc?RIIA that mediates trafficking of targets phagocytosed via Fc?RIIA to the lysosomal compartment.

Abstract: The present invention relates, in general, to phagocytosis and phagolysosomal fusion and, in particular, to a tripeptide of Fc?RIIA that mediates trafficking of targets phagocytosed via Fc?RIIA to the lysosomal compartment.

Abstract: The present invention relates, in general, to phagocytosis and phagolysosomal fusion and, in particular, to a tripeptide of Fc&ggr;RIIA that mediates trafficking of targets phagocytosed via Fc&ggr;RIIA to the lysosomal compartment.

Abstract: A method and test kit for selectively staining histamine or histamine blocker sites on mammalian cells is described. Novel fluorescently labeled histamines or histamine blocker compounds are described. The method allows the visualization of sites on individual cells which are receptors for the histamines or histamine blockers.

Abstract: A method and test kit for selectively staining histamine or histamine blocker sites on mammalian cells is described. Novel fluorescently labeled histamines or histamine blocker compounds are described. The method allows the visualization of sites on individual cells which are receptors for the histamines or histamine blockers.